By David Tuller, DrPH After Reuters ran that PACE/CBT/GET propaganda piece last month, I sent an e-mail expressing two concerns to Kate Kelland, the reporter, and the two editors listed as having worked on the story. The first concern was that the story falsely said I published my investigation on the blog of a Berkeley …
By David Tuller, DrPH Last Sunday, I sent a letter expressing my concerns about Kate Kelland’s recent article to the appropriate person–the Reuters global editor for ethics and standards. After considering the issues, Reuters has decided to add my current academic title to the post and leave everything else as is. I appreciate the first …
By David Tuller, DrPH As of this post, I have achieved 57% of my goal, with 542 donations and 15 days left to go. I think that’s pretty good! I’m optimistic about getting reasonably close to the amount I’m trying to raise. Folks at Berkeley certainly notice the success of my crowdfunding. It is an …
Trial By Error: Crowdfunding, Week 2; and more Sharpe and Chalder Read More »
By David Tuller, DrPH Last month I wrote to the director of legal services at the University of Bristol seeking information about documents from a study conducted by investigators from the institution. The study, published by BMJ Open in 2011, was called Unidentified Chronic Fatigue Syndrome/myalgic encephalomyelitis (CFS/ME) is a major cause of school absence: …
The decision by the US government to allow the resumption of experiments on aerosol transmission of avian influenza viruses has once again raised the hackles of some individuals who feel that the work is too risky. I disagree with their view on this work. Science reports that ‘Controversial lab studies that modify bird flu viruses …
Avian influenza virus transmission experiments proceed, as they should Read More »
By David Tuller, DrPH The PACE trial and other unacceptable studies from the CBT/GET ideological brigades have had an enormous impact around the world. Luckily, in the US at least, momentum seems to have finally shifted away from this bogus treatment paradigm. The shift, while welcome and long overdue, does not automatically mean more effective …
